GSK Blenrep wins FDA approval in relapsed multiple myeloma

GSK Blenrep wins FDA approval in relapsed multiple myeloma

Key Takeaways

• The FDA approved Blenrep in combination with bortezomib and dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy.
• This approval marks Blenrep's return to the U.S. market nearly three years after GSK withdrew the drug in 2022 following a failed confirmatory trial.
• Blenrep is available only through a restricted REMS program due to eye-related safety risks, creating a new layer of prescribing and access friction for the commercial launch.

IntelligenceRegulatory Impact▾

FDA decisions frame this story. Regulatory relevance is high for blood cancer, with Blenrep and belantamab mafodotin-blmf most exposed. Track designations, submission types, and label or guidance shifts that could move timelines.

FDA approval restores Blenrep after market withdrawal

GSK announced on October 23, 2025, that the FDA has approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy. The approval represents a regulatory reset for a drug that had previously exited the U.S. market.

Blenrep is a B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate designed to target a specific cancer cell surface marker. The combination regimen adds two established multiple myeloma backbone drugs—bortezomib (a proteasome inhibitor) and dexamethasone (a corticosteroid)—to the belantamab mafodotin backbone.

IntelligenceCompetitive Intelligence▾

GSK are directly implicated. Competitive pressure reads medium — compare pipeline positioning and partnership scouting against signals in this story.

Why Blenrep was withdrawn and what changed

GSK withdrew Blenrep from the U.S. market in 2022 after a confirmatory clinical trial failed. The path back to market involved a strategic shift: rather than defending monotherapy, GSK repositioned Blenrep as part of a three-drug combination, resulting in the October 2025 approval.

The new label specifies a patient population that has received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent. This represents a distinct regulatory positioning from the drug's prior status.

IntelligenceMarket Signals▾

Commercial pull is high and investment relevance high for blood cancer. Expect implications for pricing, access, and launch sequencing.

REMS restrictions and access implications

Blenrep is available in the U.S. only through a restricted program called the BLENREP Risk Evaluation and Mitigation Strategy (REMS) due to the risk of eye problems. The REMS program creates an additional layer of prescribing complexity compared to unrestricted multiple myeloma regimens.

For BD and commercial teams, the REMS requirement introduces operational considerations that will shape launch execution. The restricted distribution framework ensures that eligible patients are monitored for the identified ocular safety signal, but prescribers must navigate enrollment workflows as part of the treatment access process.

IntelligenceStrategic Takeaways▾

The FDA approved Blenrep in combination with bortezomib and dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy. This approval marks Blenrep's return to the U.S. market nearly three years after GSK withdrew the drug in 2022 following a failed confirmatory trial. Blenrep is available only through a restricted REMS program due to eye-relate

Clinical evidence supporting the combination

In the combination regimen, Blenrep helped keep multiple myeloma in remission for a median of 31 months. This durability metric reflects the clinical rationale for the three-drug approach and provides a measurable efficacy anchor for the label.

Beyond the approved indication, GSK is advancing Blenrep in additional settings. A Phase 2 trial (NCT07227311) is recruiting patients to evaluate the efficacy and safety of belantamab mafodotin in combination with standard of care for relapsed-refractory multiple myeloma. A Phase 3 trial (NCT07285239) is not yet recruiting and will compare belantamab mafodotin or daratumumab each combined with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma.

Other active trials explore alternative dosing regimens and combinations. A Phase 2 trial (NCT05847569) at Mayo Clinic is recruiting patients to test alternate doses and dosing schedules of belantamab mafodotin for triple-class refractory multiple myeloma, and a Phase 2 trial (NCT05208307) at Emory University is recruiting patients to evaluate belantamab mafodotin combined with pomalidomide and dexamethasone for high-risk myeloma.

IntelligenceEvidence Quality▾

Grounded in 1 regulatory source.

What to watch next

The immediate focus for investors and BD teams is uptake in the approved relapsed or refractory multiple myeloma population. The REMS program will be a key operational consideration; how prescribers and patients engage with the restricted distribution framework will shape commercial execution.

Medium-term catalysts include results from the Phase 2 and Phase 3 trials now underway. Data from these studies will inform whether Blenrep can be positioned in additional treatment settings beyond the current third-line-or-later indication.

Frequently Asked Questions

Related profiles

• BLENREP
• bortezomib
• dexamethasone

Related coverage

• GSK’s Blenrep returns to the US market after FDA approves resubmission
• Eli Lilly's donanemab wins FDA approval for early Alzheimer's disease
• Vabysmo gains EU approval for retinal vein occlusion: what changes next